Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

Korábbi kezelés

• Participants meeting any of the following criteria will not be eligible for study enrollment:
  • Current participation in an investigation clinical trial or expanded access program, in which the participant may be receiving voxelotor treatment.
  • Medical, psychological, or behavioral condition that, in the opinion of the study doctor, would confound or interfere with evaluation of safety and/or effectiveness of the study drug, prevent compliance with the study protocol; preclude informed consent; or render the participant unable/unlikely to comply with the study procedures

• Participants who meet all the following criteria will be eligible for enrollment:
  • Willing and able to provide written informed consent (aged ≥ 18 years), parental/ guardian consent and participant assent (aged ≥ 12 to <18 years) per local regulations, or pediatric participants (aged 4 to <12 years) with parental/guardian consent per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines
  • Male or female participants with documented diagnosis of sickle cell disease (all genotypes)
  • Undergoing treatment with Oxbryta according to the Oxbryta USPI